These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37824087)

  • 41. Targeting Ibrutinib to Tumor-Infiltrating T Cells with a Sialic Acid Conjugate-Modified Phospholipid Complex for Improved Tumor Immunotherapy.
    Li C; Fan C; Lu S; Qiu Q; Gao X; Yan X; Wang S; Zhao B; Liu X; Song Y; Deng Y
    Mol Pharm; 2023 Jan; 20(1):438-450. PubMed ID: 36382950
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tumor microcalcification-mediated relay drug delivery for photodynamic immunotherapy of breast cancer.
    Jian H; Wang X; Song P; Wu X; Zheng R; Wang Y; Zhang H
    Acta Biomater; 2022 Mar; 140():518-529. PubMed ID: 34923096
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enhanced Cellular Ablation by Attenuating Hypoxia Status and Reprogramming Tumor-Associated Macrophages via NIR Light-Responsive Upconversion Nanocrystals.
    Ai X; Hu M; Wang Z; Lyu L; Zhang W; Li J; Yang H; Lin J; Xing B
    Bioconjug Chem; 2018 Apr; 29(4):928-938. PubMed ID: 29466856
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Manipulation of the tumor immuno-microenvironment via TAM-targeted expression of transcription factors.
    Musick M; Yu X
    Immunol Res; 2022 Aug; 70(4):432-440. PubMed ID: 35486115
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Docetaxel-loaded M1 macrophage-derived exosomes for a safe and efficient chemoimmunotherapy of breast cancer.
    Zhao Y; Zheng Y; Zhu Y; Li H; Zhu H; Liu T
    J Nanobiotechnology; 2022 Aug; 20(1):359. PubMed ID: 35918698
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chimeric Peptide Engineered Bioregulator for Metastatic Tumor Immunotherapy through Macrophage Polarization and Phagocytosis Restoration.
    Chen XY; Yan MY; Liu Q; Yu BX; Cen Y; Li SY
    ACS Nano; 2023 Aug; 17(16):16056-16068. PubMed ID: 37578051
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy.
    Gao J; Liang Y; Wang L
    Front Immunol; 2022; 13():888713. PubMed ID: 35844605
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy.
    Ramesh A; Brouillard A; Kumar S; Nandi D; Kulkarni A
    Biomaterials; 2020 Jan; 227():119559. PubMed ID: 31670078
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Engineered Bacterial Biomimetic Vesicles Reprogram Tumor-Associated Macrophages and Remodel Tumor Microenvironment to Promote Innate and Adaptive Antitumor Immune Responses.
    Zheng P; He J; Fu Y; Yang Y; Li S; Duan B; Yang Y; Hu Y; Yang Z; Wang M; Liu Q; Zheng X; Hua L; Li W; Li D; Ding Y; Yang X; Bai H; Long Q; Huang W; Ma Y
    ACS Nano; 2024 Mar; 18(9):6863-6886. PubMed ID: 38386537
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Polymersomes-Mediated Delivery of CSF1R Inhibitor to Tumor Associated Macrophages Promotes M2 to M1-Like Macrophage Repolarization.
    Rodriguez-Perdigon M; Jimaja S; Haeni L; Bruns N; Rothen-Rutishauser B; Rüegg C
    Macromol Biosci; 2022 Aug; 22(8):e2200168. PubMed ID: 35624036
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide.
    Lee C; Jeong H; Bae Y; Shin K; Kang S; Kim H; Oh J; Bae H
    J Immunother Cancer; 2019 Jun; 7(1):147. PubMed ID: 31174610
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
    Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
    J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reprogramming tumor-associated macrophages by a dually targeted milk exosome system as a potent monotherapy for cancer.
    Chen Y; Gong L; Cao Y; Liu Z; Wang Y; Cheng H; Feng Y; Yao S; Yin Y; Wu Z; Huang Z
    J Control Release; 2024 Feb; 366():395-409. PubMed ID: 38184235
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of tumor-associated macrophages in tumor immune evasion.
    Huang R; Kang T; Chen S
    J Cancer Res Clin Oncol; 2024 May; 150(5):238. PubMed ID: 38713256
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Blockade of DC-SIGN
    Hu B; Wang Z; Zeng H; Qi Y; Chen Y; Wang T; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Dai B; Guo J; Xu L; Zhang W; Xu J
    Cancer Res; 2020 Apr; 80(8):1707-1719. PubMed ID: 32060149
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Significance of Immunosuppressive Cells as a Target for Immunotherapies in Melanoma and Non-Melanoma Skin Cancers.
    Fujimura T; Aiba S
    Biomolecules; 2020 Jul; 10(8):. PubMed ID: 32707850
    [TBL] [Abstract][Full Text] [Related]  

  • 58. miR‑382 inhibits breast cancer progression and metastasis by affecting the M2 polarization of tumor‑associated macrophages by targeting PGC‑1α.
    Zhou H; Gan M; Jin X; Dai M; Wang Y; Lei Y; Lin Z; Ming J
    Int J Oncol; 2022 Oct; 61(4):. PubMed ID: 36069230
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cancer cell membrane-coated nanoparticles for bimodal imaging-guided photothermal therapy and docetaxel-enhanced immunotherapy against cancer.
    Chen Q; Zhang L; Li L; Tan M; Liu W; Liu S; Xie Z; Zhang W; Wang Z; Cao Y; Shang T; Ran H
    J Nanobiotechnology; 2021 Dec; 19(1):449. PubMed ID: 34952587
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Self-Assembled Nanoparticles from the Amphiphilic Prodrug of Resiquimod for Improved Cancer Immunotherapy.
    Li JX; Shu N; Zhang YJ; Tong QS; Wang L; Zhang JY; Du JZ
    ACS Appl Mater Interfaces; 2024 May; 16(20):25665-25675. PubMed ID: 38735053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.